8-K: Carisma Therapeutics Initiates Wind-Down, Leadership Exits

Carisma Therapeutics Inc. announced the termination of its CEO and CSO, along with multiple board resignations, as it pursues an orderly wind-down of operations.

Summary

• Carisma Therapeutics Inc. expects to continue efforts to sell or monetize its remaining assets and pursue an orderly wind-down of its remaining operations.
• Steven Kelly, President and Chief Executive Officer, was notified that his employment will terminate without cause, effective November 15, 2025.
• Michael Klichinsky, Pharm.D., Ph.D., Chief Scientific Officer, was notified that his employment will terminate without cause, effective October 15, 2025.
• Mr. Kelly will receive a lump sum payment of $624,000 (12 months of base salary), a lump sum of $299,948 (100% pro-rated 2025 target bonus), and a taxable monthly payment of $3,757 for health insurance costs for up to 12 months.
• Dr. Klichinsky will receive $494,000 (12 months of base salary payable in installments), a lump sum of $155,915 (100% pro-rated 2025 target bonus), and a taxable monthly payment of $2,245 for health insurance costs for up to 12 months.
• John Hohneker, M.D., Briggs Morrison, M.D., and David Scadden M.D. resigned from the Board of Directors and all committees, effective October 15, 2025.
• Steven Kelly also resigned from the Board of Directors, effective November 15, 2025.
• The resignations were not a result of any disagreement with the company's operations, policies, or practices.
• The company expects to appoint a consultant to serve as Chief Executive Officer and manage remaining wind-down activities.

Sentiment

Score: 1

Explanation: The filing details the wind-down of company operations, termination of key executives, and mass board resignations, indicating a severe negative event for the company's future.

Positives

• NA

Negatives

• The company is pursuing an orderly wind-down of its remaining operations, indicating a cessation of core business activities.
• The President and Chief Executive Officer, Steven Kelly, and the Chief Scientific Officer, Michael Klichinsky, have been terminated without cause.
• Four directors, including the outgoing CEO, have resigned from the Board of Directors.
• The company expects to sell or monetize its remaining assets, which typically precedes liquidation.

Risks

• Ability to identify and complete asset monetization transactions.
• Ability to preserve existing cash resources.
• Ability to continue as a going concern.
• Ability to execute a planned orderly wind down.
• Other risks related to the company's business as discussed in previous SEC filings (Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025).

Future Outlook

The company expects to continue efforts to sell or monetize its remaining assets and pursue an orderly wind-down of its remaining operations. A consultant is expected to be appointed as CEO to manage these wind-down activities.

Management Comments

• "The Company expects to continue to continue to attempt to sell or otherwise dispose of or monetize its remaining assets and pursue an orderly wind down of its remaining operations."
• "Following Mr. Kellys termination, the Company expects to appoint a consultant to serve as the Companys chief executive officer and manage remaining wind-down activities."

Industry Context

This announcement signals the failure of a biotechnology company, likely due to unsuccessful clinical development, lack of funding, or inability to bring products to market. In the highly capital-intensive and risky biotech sector, such wind-downs are not uncommon when companies fail to achieve critical milestones or secure further investment. It reflects the inherent challenges and high attrition rate within the industry.

Comparison to Industry Standards

• NA. A company wind-down is not typically compared to industry standards in terms of performance, but rather represents a cessation of operations.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Significant negative impact due to the company's wind-down, likely leading to substantial loss of investment value.
• Employees: Termination of employment for key executives, implying broader workforce reductions as part of the wind-down.
• Creditors: Potential impact on ability to recover debts depending on asset monetization outcomes.

Next Steps

• Continue efforts to sell or monetize remaining assets.
• Pursue an orderly wind-down of remaining operations.
• Appoint a consultant to serve as CEO to manage wind-down activities.

Key Dates

Recommendation

The company is undergoing an orderly wind-down, terminating key executives, and experiencing mass board resignations, indicating a cessation of operations and likely eventual delisting. This situation points to a complete loss of value for shareholders.

Keywords

Carisma Therapeutics, wind-down, liquidation, executive termination, board resignation, severance, biotechnology, asset monetization, going concern, CARM